In the early 1990s, a systematic examination of HIV replication within lymphoid tissues was conducted to define the pathophysiologic consequences of infection. These studies provided evidence for a continuum of destruction of various structural elements within the lymph nodes, spleen, and thymus, and supported the involvement of the thymus in viral replication. It is presumed that most T cells are destroyed after direct viral infection. In addition, apoptosis is thought to be responsible for the loss of CD4+ and CD8+ cells.[17]Lifson JD, Reyes GR, McGrath MS, et al. AIDS retrovirus induced cytopathology: giant cell formation and involvement of CD4 antigen. Science. 1986 May 30;232(4754):1123-7.
http://www.ncbi.nlm.nih.gov/pubmed/3010463?tool=bestpractice.com
[18]Ameisen JC, Capron A. Cell dysfunction and depletion in AIDS: the programmed cell death hypothesis. Immunol Today. 1991 Apr;12(4):102-5.
http://www.ncbi.nlm.nih.gov/pubmed/1676268?tool=bestpractice.com
[19]Ameisen JC, Estaquier J, Idziorek T. From AIDS to parasite infection: pathogen-mediated subversion of programmed cell death as a mechanism for immune dysregulation. Immunol Rev. 1994 Dec;142:9-51.
http://www.ncbi.nlm.nih.gov/pubmed/7698802?tool=bestpractice.com
Perinatal transmission is the most common mode of acquisition of HIV infection in children worldwide.[20]Mofenson LM. Pregnancy and perinatal transmission of HIV infection. In: Holmes KK, Sparling PF, Stamm WE, et al, eds. Sexually transmitted diseases. 4th ed. New York, NY: McGraw-Hill; 2008:1659-93. HIV can be transmitted throughout pregnancy, during labor and delivery, and postpartum through breast milk. In resource-rich settings where the majority of infants are not breastfed, approximately one third of perinatal transmission occurs in utero and the remainder during labor or delivery. Disease progression or clinical immune deficiency, high HIV viral load, sexually transmitted infections during pregnancy, and obstetric factors such as prolonged rupture of membranes are associated with increased perinatal transmission.[21]Cooper ER, Charurat M, Mofenson L, et al; Women and Infants' Transmission Study Group. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):484-94.
http://www.ncbi.nlm.nih.gov/pubmed/11981365?tool=bestpractice.com
[22]Magder LS, Mofenson L, Paul ME, et al. Risk factors for in utero and intrapartum transmission of HIV. J Acquir Immune Defic Syndr. 2005 Jan 1;38(1):87-95.
http://www.ncbi.nlm.nih.gov/pubmed/15608531?tool=bestpractice.com
During pregnancy, the placenta provides an important physical and immune barrier between maternal and fetal circulation. It is also thought to provide protection against in-utero transmission of HIV-1 infection.[23]De Cock KM, Fowler MG, Mercier E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA. 2000 Mar 1;283(9):1175-82.
http://www.ncbi.nlm.nih.gov/pubmed/10703780?tool=bestpractice.com
The exact mechanisms of in-utero transmission are not known, but factors that disrupt placental integrity, such as chorioamnionitis, may play a role.[24]Wabwire-Mangen F, Gray RH, Mmiro FA, et al. Placental membrane inflammation and risks of maternal-to-child transmission of HIV-1 in Uganda. J Acquir Immune Defic Syndr. 1999 Dec 1;22(4):379-85.
http://www.ncbi.nlm.nih.gov/pubmed/10634200?tool=bestpractice.com
[25]Van Dyke RB, Korber BT, Popek E, et al. The Ariel Project: a prospective cohort study of maternal-child transmission of human immunodeficiency virus type 1 in the era of maternal antiretroviral therapy. J Infect Dis. 1999 Feb;179(2):319-28. [Erratum in: J Infect Dis. 1999 Mar;179(3):754.]
http://www.ncbi.nlm.nih.gov/pubmed/9878014?tool=bestpractice.com
Viral characteristics, such as viral subtype or cellular tropism, and host genetic factors, such as HLA or chemokine receptor genotype, have been reported in some studies to influence in-utero transmission.[26]Farquhar C, Rowland-Jones S, Mbori-Ngacha D, et al. Human leukocyte antigen (HLA) B*18 and protection against mother-to-child HIV type 1 transmission. AIDS Res Hum Retroviruses. 2004 Jul;20(7):692-7.
http://www.ncbi.nlm.nih.gov/pubmed/15307911?tool=bestpractice.com
[27]Kostrikis LG, Neumann AU, Thomson B, et al. A polymorphism in the regulatory region of the CC-chemokine receptor 5 gene influences perinatal transmission of human immunodeficiency virus type 1 to African-American infants. J Virol. 1999 Dec;73(12):10264-71.
http://jvi.asm.org/content/73/12/10264.full
http://www.ncbi.nlm.nih.gov/pubmed/10559343?tool=bestpractice.com
[28]LaRussa P, Magder LS, Pitt J, et al; Women and Infants Transmission Study. Association of HIV-1 viral phenotype in the MT-2 assay with perinatal HIV transmission. J Acquir Immune Defic Syndr. 2002 May 1;30(1):88-94.
http://www.ncbi.nlm.nih.gov/pubmed/12048368?tool=bestpractice.com
[29]Renjifo B, Gilbert P, Chaplin B, et al; Tanzanian Vitamin and HIV Study Group. Preferential in-utero transmission of HIV-1 subtype C as compared to HIV-1 subtype A or D. AIDS. 2004 Aug 20;18(12):1629-36.
http://www.ncbi.nlm.nih.gov/pubmed/15280773?tool=bestpractice.com
[30]Winchester R, Pitt J, Charurat M, et al. Mother-to-child transmission of HIV-1: strong association with certain maternal HLA-B alleles independent of viral load implicates innate immune mechanisms. J Acquir Immune Defic Syndr. 2004 Jun 1;36(2):659-70.
http://www.ncbi.nlm.nih.gov/pubmed/15167284?tool=bestpractice.com
[31]Yang C, Li M, Newman RD, et al. Genetic diversity of HIV-1 in western Kenya: subtype-specific differences in mother-to-child transmission. AIDS. 2003 Jul 25;17(11):1667-74.
http://www.ncbi.nlm.nih.gov/pubmed/12853749?tool=bestpractice.com
The majority of in-utero transmission is thought to occur late in pregnancy.[32]Rouzioux C, Costagliola D, Burgard M, et al. Estimated timing of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission by use of a Markov model. The HIV Infection in Newborns French Collaborative Study Group. Am J Epidemiol. 1995 Dec 15;142(12):1330-7.
http://www.ncbi.nlm.nih.gov/pubmed/7503054?tool=bestpractice.com
[33]Kourtis AP, Bulterys M, Nesheim SR, et al. Understanding the timing of HIV transmission from mother to infant. JAMA. 2001 Feb 14;285(6):709-12.
http://www.ncbi.nlm.nih.gov/pubmed/11176886?tool=bestpractice.com
The mechanisms by which intrapartum transmission occurs are by direct access of cell-free or cell-associated virus to the infant systemic circulation through maternal-fetal transfusion. Maternal-fetal transfusion occurs during uterine contractions in labor, or by the infant swallowing HIV virus-containing genital tract fluid during delivery, with viral passage through the infant's gastrointestinal mucosa to underlying lymphoid cells followed by systemic dissemination.[20]Mofenson LM. Pregnancy and perinatal transmission of HIV infection. In: Holmes KK, Sparling PF, Stamm WE, et al, eds. Sexually transmitted diseases. 4th ed. New York, NY: McGraw-Hill; 2008:1659-93. In mothers who are not virally suppressed, breast milk contains high levels of the HIV virus, and transmission can occur at any point during lactation.[34]Tersmette M, Gruters RA, de Wolf F, et al. Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J Virol. 1989 May;63(5):2118-25.
http://jvi.asm.org/content/63/5/2118.full.pdf+html
http://www.ncbi.nlm.nih.gov/pubmed/2564898?tool=bestpractice.com
[35]Schwartz S, Felber BK, Fenyo EM, et al. Rapidly and slowly replicating human immunodeficiency virus type 1 isolates can be distinguished according to target-cell tropism in T-cell and monocyte cell lines. Proc Natl Acad Sci U S A. 1989 Sep;86(18):7200-3.
http://www.pnas.org/content/86/18/7200.full.pdf+html
http://www.ncbi.nlm.nih.gov/pubmed/2789383?tool=bestpractice.com
[36]Fenyo EM, Albert J, Asjo B. Replicative capacity, cytopathic effect and cell tropism of HIV. AIDS. 1989;3 (suppl 1):S5-12.
http://www.ncbi.nlm.nih.gov/pubmed/2514754?tool=bestpractice.com
[37]Shapiro RL, Hughes MD, Ogwu A, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med. 2010 Jun 17;362(24):2282-94.
http://www.ncbi.nlm.nih.gov/pubmed/20554983?tool=bestpractice.com
High maternal viral load (in plasma and in breast milk), breast milk immunologic factors, maternal breast pathology (such as mastitis, cracked or bleeding nipples, abscesses), and low maternal CD4 count are associated with increased risk of transmission through breast-feeding. Infant gastrointestinal pathology, such as candidiasis, may disrupt mucosal integrity and aid viral transmission.[38]Fowler MG, Newell ML. Breast-feeding and HIV-1 transmission in resource-limited settings. J Acquir Immune Defic Syndr. 2002 Jun 1;30(2):230-9.
http://www.ncbi.nlm.nih.gov/pubmed/12045686?tool=bestpractice.com
[39]Leroy V, Karon JM, Alioum A, et al; West Africa PMTCT Study Group. Twenty-four month efficacy of a maternal short-course zidovudine regimen to prevent mother-to-child transmission of HIV-1 in West Africa. AIDS. 2002 Mar 8;16(4):631-41.
http://www.ncbi.nlm.nih.gov/pubmed/11873008?tool=bestpractice.com
[40]Wiktor SZ, Ekpini E, Karon JM, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte d'Ivoire: a randomised trial. Lancet. 1999 Mar 6;353(9155):781-5.
http://www.ncbi.nlm.nih.gov/pubmed/10459958?tool=bestpractice.com
[41]John-Stewart G, Mbori-Ngacha D, Ekpini R, et al; Ghent IAS Working Group on HIV in Women and Children. Breast-feeding and transmission of HIV-1. J Acquir Immune Defic Syndr. 2004 Feb 1;35(2):196-202.
http://www.ncbi.nlm.nih.gov/pubmed/14722454?tool=bestpractice.com
[42]World Health Organization. Guideline: updates on HIV and infant feeding. 2016 [internet publication].
https://www.who.int/publications/i/item/9789241549707